RT Journal Article
SR Electronic
T1 Variation in price of cardiovascular and diabetes medicine in Indonesia, and relationship with quality: a mixed methods study in East Java
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.24.22282722
DO 10.1101/2022.11.24.22282722
A1 Pisani, Elizabeth
A1 Dewi, Aksari
A1 Palagyi, Anna
A1 Praveen, Devarsety
A1 Pratita Ihsan, Bachtiar Rifai
A1 Hariadini, Ayuk Lawuningtyas
A1 Lyrawati, Diana
A1 Sujarwoto,
A1 Maharani, Asri
A1 Tampubolon, Gindo
A1 Patel, Anushka
YR 2022
UL http://medrxiv.org/content/early/2022/11/27/2022.11.24.22282722.abstract
AB Lower-middle income Indonesia, the world’s fourth most populous country, has struggled to contain costs in its mandatory, single-payer public health insurance system since the system’s inception in 2014. Public procurement policies radically reduced prices of most medicines in public facilities and the wider market. However, professional associations and the press have questioned the quality of these low-cost, unbranded generic medicines.We collected 204 samples of 4 cardiovascular and 1 antidiabetic medicine from health facilities and retail outlets in East Java. We collected amlodipine, captopril, furosemide, simvastatin and glibenclamide, sampling to reflect patients’ likelihood of exposure to specific brands and outlets. We recorded sales prices and maximum retail prices, and tested medicines for dissolution and percent of labelled content, using high-performance liquid chromatography. We conducted in-depth interviews with supply chain actors.All samples, including those provided free in public facilities, met quality specifications.Most manufacturers make both branded and unbranded medicines. Retail prices varied widely. The median ratio of price to the lowest price for an equivalent product was 5.1, and a few brands sold for over 100 times the minimum price. Prices also varied between outlets for identical products, as retail pharmacies set prices to maximize profit. Since very low-cost medicines were universally available and of good quality, we believe richer patients who chose to buy branded products effectively protected medicine quality for poorer patients in Indonesia, because manufacturers cross-subsidize between branded and unbranded versions of the same medicine.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by the National Health and Medical Research Council (NHMRC) of Australia under grant number NHMRC APP1149987Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Malang District Department of Health gave written permission for the study (070/1102/35.07.103/2020). The study also received ethics approval from the Ethical Committee, Ministry of Research, Technology, and Higher Education, Medical Faculty of Brawijaya University (No.83/EC/KEPK/04/2020) and the Human Research Ethic Committee of University of New South Wales, Sydney (HC200148). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUnderlying data and analytic code are provided in the Dataverse repository at: https://doi.org/10.7910/DVN/IQ6HRF https://doi.org/10.7910/DVN/IQ6HRF